ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Both my parents use CPAP machines to treat their sleep apnea so ... but there are also bundles for ResMed AirSense 10 ($339), Fisher & Paykel ICON ($339), and others. The white sanitizing chamber ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

In a report released on January 31, David Low from J.P. Morgan maintained a Buy rating on Resmed (RMD – Research Report), with a price target ...

ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep.

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...